menu
    • menu
    [{"orgOrder":0,"company":"Capstan Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"CPTX2309","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Capstan Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capstan Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Capstan Therapeutics \/ RA Capital Management"}]

    Find Immunology Clinical Drug Pipeline Developments & Deals by Capstan Therapeutics

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Capstan Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed

                            Capstan Therapeutics

                            U.S.A arrow
                            DIA 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CPTX2309

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $175.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Capstan Therapeutics Announces $175M Oversubscribed Series B Financing

                            Details : Proceeds will advance CPTX2309, Capstan’s CAR-T candidate, to early clinical proof-of-concept in autoimmune disorders and develop its tLNP pipeline.

                            Product Name : CPTX2309

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            March 20, 2024

                            Lead Product(s) : CPTX2309

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : RA Capital Management

                            Deal Size : $175.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth